Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 15 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR Reflections from our chief clinician: The essential role of our research... February 4, 2022 EMA Recommends Extending Indications for Lisocabtagene Maraleucel November 12, 2025 Improving Cancer Immunotherapy: Overcoming the Problem of ‘Exhausted’ T Cells July 18, 2019 Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and... December 17, 2024 Load more HOT NEWS Molecular Burglary: Cancer Cells Hijack Energy from Immune Cells When You Lose a Spouse to Cancer and Need Support Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative...
